Apellis Pharmaceuticals has been slowly rebounding from an unjustified safety scare related to its approved treatment for a common type of vision loss. Now, a competing medicine from Astellas, also recently approved, may have stumbled, which could further boost Apellis’ business outlook — and its stock price.
In a statement released Monday night, Astellas announced the “positive” outcome of an important follow-up analysis meant to demonstrate the two-year efficacy of its drug, called Izervay, in people with geographic atrophy.
I’m skeptical. The bulk of Astellas’ announcement reads like a spin job. And when I asked the company for clarifying information, it waited an entire day before responding.
This article is exclusive to STAT+ subscribers
Unlock this article — plus in-depth analysis, newsletters, premium events, and networking platform access.
Already have an account? Log in
Already have an account? Log in
About the Author Reprints
To submit a correction request, please visit our Contact Us page.
STAT encourages you to share your voice. We welcome your commentary, criticism, and expertise on our subscriber-only platform, STAT+ Connect